



# HIV PREVENTION

REVIEW MEETING

VIRTUAL | 30 - 31 MARCH 2022

Program



Dear Colleagues,

Following the success of last year's Prevention Series, we are delighted to welcome you to the **HIV Prevention Review Meeting 2022!** Raising awareness, sharing expertise, and building a strong HIV prevention research and practice community are critical priorities as we enter our 5th decade of the epidemic.

Despite the significant global challenges of the past two years, biomedical HIV prevention continues to move forward with novel drugs, formulations, and devices entering the prevention toolkit and more on the horizon. We invite you to join us in a detailed review of recent scientific advances, with emphasis on real-world implications and implementation.

The state-of-the-art program features keynote lectures by leading experts, lively and engaging panel discussions, pro-con debates, and interactive Q&A sessions. Viewpoints from both healthcare providers and community advocates will provide robust opportunities to consider both the promise of new discoveries and the challenges that must be addressed for effective implementation.

This year's sessions include:

- What's New in PEP and PrEP?
- Pro-Con Debate: Long-Acting Drugs Will Solve the Problem with Adherence and Persistence in PrEP
- HIV Prevention in Underrepresented Populations
- Panel Discussion - Can We Ever Control HIV in the Absence of Vaccines?

We look forward to meeting you virtually on 30 and 31 March!

Sincerely,  
Mauro Schechter and K. Rivet Amico



**Mauro Schechter,  
MD, PhD**

Federal University of Rio  
de Janeiro, Brazil

*Program Director*



**K. Rivet Amico,  
PhD**

University of Michigan,  
United States

*Program Director*



# General Information

## Certificate of Attendance

Certificates of attendance will be sent by e-mail after completion of the post-meeting survey.

## Feedback

Your feedback is very valuable to us and enables us to further improve this meeting. After each session, a short questionnaire will pop up and we would like to ask you to take a minute to complete it. After the meeting, a survey will be sent to you via email, with further questions on how this summit could be improved.

## Networking

The Meeting Hub allows you to connect and communicate with other attendees. Once you have located an attendee you want to connect with, click the Connect button. Once the other attendee accepts your request, you can choose to interact by starting a live chat or live video call. You can also schedule a meeting at a later time, send messages, and take notes. Contact information for all attendees you have connected with will be included when you export contacts.

## Notes

You will be able to take notes during the meeting. Any notes that you take throughout the event can be exported by selecting the Export icon in the top right of the screen near your Profile image.

## Social Media

We encourage you to post news and tweet about [#HIVPreventionReview](#) to your social media accounts as often as you like during the meeting. You can either post your own tweets to your followers using the hashtag [#HIVPreventionReview](#) or retweet a message through the official [@Virology\\_Edu account](#).

## Presentations and Webcasts

**ame** Webcasts of the presentations along with the PDF presentations will be available on [www.AcademicMedicalEducation.com](http://www.AcademicMedicalEducation.com) three weeks after the meeting. You will be able to watch the presentations on the virtual meeting portal until three weeks after the meeting.

## Time Zones

Times are in Central European Summer Time. If you need to convert the times to your timezone, this website might be of interest to you: [www.worldtimebuddy.com](http://www.worldtimebuddy.com)

## Virtual Platform

OnAIR is the virtual platform being used for HIV Prevention Review Meeting 2022.

A video tutorial on how to use the virtual platform can be found [here](#).

## Our Team



**Rikke Puggaard-Rode**  
Project Manager  
[Rikke.Rode@amededu.com](mailto:Rikke.Rode@amededu.com)



**Eva Vamvounaki**  
Junior Project Coordinator  
[Eva.Vamvounaki@amededu.com](mailto:Eva.Vamvounaki@amededu.com)

Disclaimer: This meeting aims to offer participants the opportunity to share information. Virology Education cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this meeting. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the meeting.



**The HIV Prevention Review Meeting 2022**, Utrecht (Livestream), Netherlands, 30/03/2022 - 31/03/2022 has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **4 European CME credits (ECMEC®s)**. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credit to AMA credit can be found at [www.ama-assn.org/education/earn-credit-participation-international-activities](http://www.ama-assn.org/education/earn-credit-participation-international-activities).

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

#### **EACCME® credits**

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation at the event once he/she has completed the feedback form.

An online survey will be sent out to all attendees at the end of the meeting. After completing the survey, a CME certificate will be sent to your registration email. If you have any questions regarding claiming CME credits, please contact [eva.vamvounaki@amededu.com](mailto:eva.vamvounaki@amededu.com). Please note that CME accreditation is only provided for delegates that attend the event livestream.



## Wednesday, 30 March 2022

Times are in Central European Summer Time (CEST)

<b>Day 1</b>	
<i>Program Directors: Mauro Schechter &amp; K. Rivet Amico</i>	
<b>Opening of the Meeting</b>	
6:00 PM	<b>Welcome, Introductions, and Goals</b> <b>Mauro Schechter, MD, PhD</b> Federal University of Rio de Janeiro, Brazil <b>K. Rivet Amico, PhD</b> University of Michigan, United States
<b>Session 1</b>	<b>What's New in PEP and PrEP?</b> <i>Chair: Mauro Schechter &amp; K. Rivet Amico</i>
6:10 PM	<b>Existing Drugs and Strategies for PEP</b> <b>Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD, PGD (Research Ethics), MBE (Bioethics), CIP</b> Kenya Medical Research Institute, Kenya <b>Victor Ocholla Omollo, MBChB, MPH</b> Kenya Medical Research Institute, Kenya
6:30 PM	<b>Existing Drugs and Strategies for PrEP</b> <b>Richard Elion, MD</b> George Washington School of Medicine, United States
6:50 PM	<b>New Drugs and Strategies for PrEP and What This Means for PEP?</b> <b>Sheena McCormack, MD</b> Medical Research Council (MRC), United Kingdom
7:10 PM	<b>Roundtable Discussion</b>
7:30 PM	Virtual Coffee Break - Time to Network
<b>Session 2</b>	<b>Pro-Con Debate: Long-Acting Drugs Will Solve the Problem with Adherence and Persistence in PrEP</b> <i>Chair: Mauro Schechter &amp; K. Rivet Amico</i>
7:45 PM	<b>Introduction</b> <b>Mauro Schechter, MD, PhD</b> Federal University of Rio de Janeiro, Brazil
7:50 PM	<b>Voting</b>
7:55 PM	<b>PRO: Healthcare Provider and Community Perspectives</b> <b>Gustavo Lopardo, MD</b> University of Buenos Aires / Hospital Municipal Dr Bernardo Houssay de Vicente López / FUNCEI, Argentina <b>Alessandra Ramos</b> Human Rights Activist, Brazil
8:05 PM	<b>CON: Healthcare Provider and Community Perspectives</b> <b>François Venter, MD, FCP, PhD</b> Ezintsha, University of the Witwatersrand, South Africa <b>Maureen Luba</b> AVAC, United States/Malawi
8:15 PM	<b>Discussion with the Audience</b>
8:40 PM	<b>Rebuttals</b>
8:46 PM	<b>Voting</b>
8:50 PM	<b>Closing</b>
<b>Closing Words</b>	
8:55 PM	<b>K. Rivet Amico, PhD</b> University of Michigan, United States
9:00 PM	End of Day 1



## Thursday, 31 March 2022

Times are in Central European Summer Time (CEST)

### Day 2

Program Directors: Mauro Schechter & K. Rivet Amico

- 6:00 PM **Opening of Day 2**  
**Mauro Schechter, MD, PhD**  
 Federal University of Rio de Janeiro, Brazil

### Session 3 HIV Prevention in Underrepresented Populations

Chairs: Mauro Schechter & K. Rivet Amico

- 6:10 PM **HIV Prevention in Women**  
**Dazon Dixon Diallo, DHL, MPH**  
 SisterLove, United States
- 6:30 PM **HIV Prevention in Adolescents**  
**Sybil Hosek, PhD**  
 John H. Stroger, Jr. Hospital of Cook County, United States
- 6:50 PM **HIV Prevention in Transgender People**  
**Kai J. Jonas, PhD**  
 University of Maastricht, The Netherlands

7:10 PM **Q&A**

7:30 PM Virtual Coffee Break - Time to Network

### Session 4 Panel Discussion - Can We Ever Control HIV in the Absence of Vaccines?

Chairs: Mauro Schechter & K. Rivet Amico

- 7:45 PM **Introductory Lecture: Vaccines and Monoclonal Antibodies**  
**Shelly Karuna, MD, MPH**  
 HIV Vaccine Trials Network | COVID Prevention Trials Network Fred Hutchinson Cancer Research Center, United States
- 8:05 PM **Panel Discussion**  
**Katharine Bar, MD**  
 Perelman School of Medicine, University of Pennsylvania, United States  
**Giulio Maria Corbelli**  
 HVTN, Fred Hutchinson Cancer Research Center, United States  
**Shelly Karuna, MD, MPH**  
 HVTN, COVID Prevention Trials Network, Fred Hutchinson Cancer Research Center, United States  
**Kenneth Ngure, PhD**  
 Jomo Kenyatta University of Agriculture and Technology, Kenya  
**Carlos del Rio, MD**  
 Emory School of Medicine & Grady Health System, United States  
**Kathryn Stephenson, MD, MPH**  
 Beth Israel Deaconess Medical Center, United States

### Summary and Closure

- 8:50 PM **Closure of HIV Prevention Review 2022**  
**Mauro Schechter, MD, PhD**  
 Federal University of Rio de Janeiro, Brazil  
**K. Rivet Amico, PhD**  
 University of Michigan, United States

9:00 PM End of the Meeting

# Speakers



## **Katharine Bar, MD**

Perelman School of Medicine,  
University of Pennsylvania,  
United States

[View Bio >](#)



## **Elizabeth Anne Bukusi, MBChB, M.Med (ObGyn), MPH, PhD, PGD (Research Ethics), MBE (Bioethics), CIP**

Kenya Medical Research Institute, Kenya

[View Bio >](#)



## **Giulio Maria Corbelli**

HIV Vaccine Trials Network,  
Italy

[View Bio >](#)



## **Carlos del Rio, MD**

Emory School of Medicine & Grady Health  
System,  
United States

[View Bio >](#)



## **Dazon Dixon Diallo, DHL, MPH**

SisterLove,  
United States

[View Bio >](#)



## **Richard Elion, MD**

Washington Health Institute,  
United States

[View Bio >](#)



## **Sybil Hosek, PhD**

John H. Stroger, Jr. Hospital of Cook  
County,  
United States

[View Bio >](#)



## **Kai J. Jonas, PhD**

University of Maastricht,  
The Netherlands

[View Bio >](#)



## **Shelly Karuna, MD, MPH**

HIV Vaccine Trials Network / COVID  
Prevention Trials Network Fred  
Hutchinson Cancer Research Center,  
United States

[View Bio >](#)



## **Gustavo Lopardo, MD**

University of Buenos Aires / Hospital  
Municipal Dr Bernardo Houssay de  
Vicente López / FUNCEI,  
Argentina

[View Bio >](#)



## **Maureen Luba**

AIDS Vaccine Advocacy Coalition,  
Malawi

[View Bio >](#)



## **Sheena McCormack, MD**

Medical Research Council (MRC), United  
Kingdom

[View Bio >](#)



## **Kenneth Ngunjiri, MPH, MSc, PhD**

Jomo Kenyatta University of  
Agriculture and Technology,  
Kenya

[View Bio >](#)



## **Victor Ocholla Omollo, MBChB, MPH**

Kenya Medical Research Institute, Kenya

[View Bio >](#)



## **Alessandra Ramos**

Human Rights Activist,  
Brazil

[View Bio >](#)



## **Kathryn Stephenson, MD, MPH**

Harvard Medical School / Ragon Institute  
/ Beth Israel Deaconess Medical Center,  
United States

[View Bio >](#)



## **François Venter, MD, FCP, PhD**

Ezintsha, University of the  
Witwatersrand,  
South Africa

[View Bio >](#)



## ENDORSERS





